Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cyclopenta(c)pyrrole-2(1h)-carboxamide, Hexahydro-n-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3a Alpha,5 Alpha,6a Alpha)-
2. Ivarmacitinib Sulfate
3. Shr0302
4. Shr0302 Base
1. Shr0302
2. 1445987-21-2
3. Ivarmacitinib [usan]
4. Unii-k6k4b9z5tv
5. K6k4b9z5tv
6. (3as,6ar)-n-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrole-2-carboxamide
7. Shr-0302
8. Shr0302 Base
9. Ivarmacitinib [inn]
10. Shr0302 Free Base
11. Shr-0302 Free Base
12. Schembl15077696
13. Schembl15077710
14. Schembl16191633
15. Gtpl11878
16. Ex-a5101
17. Who 11823
18. Ncgc00687790-01
19. Ac-36766
20. Example 34 [wo2013091539a1]
21. Hy-112724
22. Cs-0062969
23. Us9527851, 34
24. Us9527851, 74
25. (3ar,5s,6as)-n-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl (7h-pyrrolo(2,3- D)pyrimidin-4-yl)amino) Hexahydrocyclopenta(c)pyrrole-2(1h)-carboxamide
26. (3ar,5s,6as)-n-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl (7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino) Hexahydrocyclopenta(c)pyrrole-2(1h)-carboxamide
27. (3ar,6as)-n-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrole-2-carboxamide
28. Cyclopenta(c)pyrrole-2(1h)-carboxamide, Hexahydro-n-(3-methoxy-1,2,4- Thiadiazol-5-yl)-5-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3a.alpha.,5.alpha.,6a.alpha.)-
29. Cyclopenta(c)pyrrole-2(1h)-carboxamide, Hexahydro-n-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3aalpha,5alpha,6aalpha)-
30. Rel-(3ar,5s,6as)-n-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1h)-carboxamide
| Molecular Weight | 414.5 g/mol |
|---|---|
| Molecular Formula | C18H22N8O2S |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 414.15864315 g/mol |
| Monoisotopic Mass | 414.15864315 g/mol |
| Topological Polar Surface Area | 140 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 600 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
Click Us!
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33027
Submission : 2018-08-21
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33027
Submission : 2018-08-21
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
ARQ-255 (ivarmacitinib) is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for alopecia areata.
Lead Product(s): Ivarmacitinib
Therapeutic Area: Dermatology Brand Name: ARQ-255
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2024
Lead Product(s) : Ivarmacitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
Details : ARQ-255 (ivarmacitinib) is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for alopecia areata.
Brand Name : ARQ-255
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 05, 2024
Details:
SHR0302, an investigational selective Janus kinase type 1 (JAK1) inhibitor, met primary and key secondary endpoints in Reistone Biopharma's Phase 2 Clinical Study (AMBER2) for the treatment of patients with moderate to severe ulcerative colitis (UC).
Lead Product(s): Ivarmacitinib
Therapeutic Area: Gastroenterology Brand Name: SHR0302
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Lead Product(s) : Ivarmacitinib
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SHR0302, an investigational selective Janus kinase type 1 (JAK1) inhibitor, met primary and key secondary endpoints in Reistone Biopharma's Phase 2 Clinical Study (AMBER2) for the treatment of patients with moderate to severe ulcerative colitis (UC).
Brand Name : SHR0302
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 20, 2021
Details:
SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance. Several late stage clinical studies are on-going in Ulcerative Colitis, Crohn's disease, etc.
Lead Product(s): Ivarmacitinib
Therapeutic Area: Dermatology Brand Name: SHR0302
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Lead Product(s) : Ivarmacitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance. Several late stage clinical studies are on-going in Ulcerative Colitis, Crohn's disease, etc...
Brand Name : SHR0302
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
